These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19541822)

  • 41. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.
    Lehman JA; Waning DL; Batuello CN; Cipriano R; Kadakia MP; Mayo LD
    J Biol Chem; 2011 Oct; 286(42):36631-40. PubMed ID: 21873427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.
    Smolewski P; Szmigielska-Kaplon A; Cebula B; Jamroziak K; Rogalinska M; Kilianska Z; Robak T
    Leuk Lymphoma; 2005 Jan; 46(1):87-100. PubMed ID: 15621786
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
    Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
    Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
    Gowda A; Roda J; Hussain SR; Ramanunni A; Joshi T; Schmidt S; Zhang X; Lehman A; Jarjoura D; Carson WE; Kindsvogel W; Cheney C; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 May; 111(9):4723-30. PubMed ID: 18182577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
    Podhorecka M; Macheta A; Chocholska S; Bojarska-Junak A; Szymczyk A; Goracy A; Dmoszynska A; Hus M
    Ann Hematol; 2016 Feb; 95(3):425-35. PubMed ID: 26692089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
    Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI
    Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
    Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
    Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
    Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation.
    Melino G; Bernassola F; Ranalli M; Yee K; Zong WX; Corazzari M; Knight RA; Green DR; Thompson C; Vousden KH
    J Biol Chem; 2004 Feb; 279(9):8076-83. PubMed ID: 14634023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.